When bamlanivimab gained initial authorization 13 months ago, it was the first drug specifically designed to arrest infections of the SARS-CoV-2 virus that causes COVID-19. …
The antibody treatments from Regeneron and Eli Lilly have been proven effective in reducing the risk of hospitalization or death from COVID-19 in certain high-risk …
